Tags

Type your tag names separated by a space and hit enter

A randomised, double-blind study comparing the efficacy and tolerability of controlled-release doxazosin and tamsulosin in the treatment of benign prostatic hyperplasia in Brazil.
Int J Clin Pract. 2006 Oct; 60(10):1172-7.IJ

Abstract

Brazilian patients with benign prostatic hyperplasia were randomised in a 12-week, double-blind, double-dummy study to receive doxazosin gastrointestinal therapeutic system (GITS) 4 mg q.i.d. (n = 82) or tamsulosin 0.4 q.i.d. (n = 83). Primary endpoints were the absolute and percentage change from baseline in symptoms measured by International Prostate Symptom Score (IPSS). Secondary endpoints included IPSS, quality-of-life (QOL) question from the IPSS, and questions 6 and 7 of the Sexual Function Abbreviated Questionnaire (SFAQ) at weeks 4 and 12. Doxazosin GITS and tamsulosin improved IPSS with no significant differences between groups at week 12. During weeks 4-8, tamsulosin-treated patients demonstrated a slower improvement (p < 0.001) in IPSS than doxazosin GITS-treated patients. The proportion of satisfied patients was observed earlier with doxazosin GITS (p = 0.006) vs. tamsulosin. At week 12, the proportion of patients with little or no difficulty at ejaculation (Q6 of SFAQ) was higher in the doxazosin GITS group (p = 0.019). Both treatments were well tolerated.

Authors+Show Affiliations

IMEG, São Paulo, Brazil. pompeuro@uol.com.brNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

16942589

Citation

Pompeo, A C L., et al. "A Randomised, Double-blind Study Comparing the Efficacy and Tolerability of Controlled-release Doxazosin and Tamsulosin in the Treatment of Benign Prostatic Hyperplasia in Brazil." International Journal of Clinical Practice, vol. 60, no. 10, 2006, pp. 1172-7.
Pompeo AC, Rosenblatt C, Bertero E, et al. A randomised, double-blind study comparing the efficacy and tolerability of controlled-release doxazosin and tamsulosin in the treatment of benign prostatic hyperplasia in Brazil. Int J Clin Pract. 2006;60(10):1172-7.
Pompeo, A. C., Rosenblatt, C., Bertero, E., DA Ros, C. T., Cairoli, C. E., Damião, R., Wroclawski, E. R., Koff, W. J., Mesquita, F., & Pinheiro, G. E. (2006). A randomised, double-blind study comparing the efficacy and tolerability of controlled-release doxazosin and tamsulosin in the treatment of benign prostatic hyperplasia in Brazil. International Journal of Clinical Practice, 60(10), 1172-7.
Pompeo AC, et al. A Randomised, Double-blind Study Comparing the Efficacy and Tolerability of Controlled-release Doxazosin and Tamsulosin in the Treatment of Benign Prostatic Hyperplasia in Brazil. Int J Clin Pract. 2006;60(10):1172-7. PubMed PMID: 16942589.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A randomised, double-blind study comparing the efficacy and tolerability of controlled-release doxazosin and tamsulosin in the treatment of benign prostatic hyperplasia in Brazil. AU - Pompeo,A C L, AU - Rosenblatt,C, AU - Bertero,E, AU - DA Ros,C T, AU - Cairoli,C E D, AU - Damião,R, AU - Wroclawski,E R, AU - Koff,W J, AU - Mesquita,F, AU - Pinheiro,G E, AU - ,, Y1 - 2006/08/24/ PY - 2006/9/1/pubmed PY - 2007/4/27/medline PY - 2006/9/1/entrez SP - 1172 EP - 7 JF - International journal of clinical practice JO - Int J Clin Pract VL - 60 IS - 10 N2 - Brazilian patients with benign prostatic hyperplasia were randomised in a 12-week, double-blind, double-dummy study to receive doxazosin gastrointestinal therapeutic system (GITS) 4 mg q.i.d. (n = 82) or tamsulosin 0.4 q.i.d. (n = 83). Primary endpoints were the absolute and percentage change from baseline in symptoms measured by International Prostate Symptom Score (IPSS). Secondary endpoints included IPSS, quality-of-life (QOL) question from the IPSS, and questions 6 and 7 of the Sexual Function Abbreviated Questionnaire (SFAQ) at weeks 4 and 12. Doxazosin GITS and tamsulosin improved IPSS with no significant differences between groups at week 12. During weeks 4-8, tamsulosin-treated patients demonstrated a slower improvement (p < 0.001) in IPSS than doxazosin GITS-treated patients. The proportion of satisfied patients was observed earlier with doxazosin GITS (p = 0.006) vs. tamsulosin. At week 12, the proportion of patients with little or no difficulty at ejaculation (Q6 of SFAQ) was higher in the doxazosin GITS group (p = 0.019). Both treatments were well tolerated. SN - 1368-5031 UR - https://www.unboundmedicine.com/medline/citation/16942589/A_randomised_double_blind_study_comparing_the_efficacy_and_tolerability_of_controlled_release_doxazosin_and_tamsulosin_in_the_treatment_of_benign_prostatic_hyperplasia_in_Brazil_ L2 - https://doi.org/10.1111/j.1742-1241.2006.01107.x DB - PRIME DP - Unbound Medicine ER -